VANGL1 (D1J7X) Rabbit mAb #14783
- WB
Supporting Data
| REACTIVITY | H M R Hm Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 60 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Hm-Hamster
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
VANGL1 (D1J7X) Rabbit mAb recognizes endogenous levels of total VANGL1 protein. This antibody does not cross-react with VANGL2 protein.
Species Reactivity:
Human, Mouse, Rat, Hamster, Monkey
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Chicken, Bovine, Pig, Horse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu309 of human VANGL1 protein.
Background
Van Gogh-like proteins (VANGL1, VANGL2) are human orthologs of Drosophila Van Gogh (Vang/Stbm), a multi-pass transmembrane protein that is required to establish cell polarity in embryonic eyes, legs, and bristles (1,2). As in Drosophila, mammalian VANGL proteins are core components of the planar cell polarity (PCP) pathway that promotes asymmetric orientation of cells across a planar surface, and drives convergence-extension movements that are critical for tissue morphogenesis (3). Mutations in the human VANGL1 gene have been identified in patients diagnosed with neural tube defects (e.g., spina bifida), providing evidence that VANGL1 plays a role in human embryonic morphogenesis (4,5). These findings are supported by genetic studies in mice, where mutations in both Vangl1 and Vangl2 result in neural tube defects (6,7). A possible role for VANGL in tumor progression is suggested by an increased expression of VANGL1 mRNA in breast cancer patients with an elevated risk of relapse (8).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.